VUITY (pilocarpine hydrochloride) · AbbVie
VUITY is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults. It is designed to improve near and intermediate visual acuity by inducing miosis, which increases the depth of focus. The formulation is optimized to enhance near vision while allowing the eye to maintain some pupillary response to light.
How VUITY Works
Pilocarpine hydrochloride acts as a cholinergic agonist that activates muscarinic receptors on the iris sphincter and ciliary muscles. Contraction of the iris sphincter leads to pupillary constriction (miosis), creating a pinhole effect that increases the depth of focus. Additionally, contraction of the ciliary muscle may result in a myopic shift, further assisting in the resolution of near-range objects.
Details
- Status
- Discontinued
- First Approved
- 2021-10-28
- Patent Cliff
- 2039
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
VUITY Approval History
What VUITY Treats
1 indicationsVUITY is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Presbyopia
VUITY Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to VUITY
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
AbbVie's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VUITY FDA Label Details
Indications & Usage
FDA Label (PDF)VUITY ® is indicated for the treatment of presbyopia in adults. VUITY is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.
VUITY Patents & Exclusivity
Patents (2 active)
Exclusivity
Pro Intelligence Preview
Deep insights for VUITY
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2039
- • 6 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 3 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.